NHS Logo
Bedfordshire and Luton Joint Formulary
Bedfordshire Hospitals NHS Foundation Trust
Bedfordshire, Luton and Milton Keynes ICB
Formulary items found
Status Description Section
REDCetuximab Erbitux® Malignant disease and immunosuppression, Cetuximab, 08.01.05
REDEncorafenib 50mg, 75mg Braftovi ®
(Capsules) 		Malignant disease and immunosuppression, Other antineoplastic drugs, 08.01.05
Searchiing the National BNF we found these items - Click button under Local to search local formulary or BNF to view on online BNF.
Local BNF Section
Cetuximab Cetuximab [Specialist Drug] Malignant Disease, Antibody Responsive Malignancy, Antineoplastic Drugs Monoclonal Antibodies
Selecting a button in the local column will search the local formulary again for the word on the button. Where the button is in outline no local match at drug name level was found.
Links found
NICE TA 668 Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer
NICE TA118: Colorectal cancer (metastatic) - bevacizumab & cetuximab
NICE TA242: Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review)
NICE TA242: Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review)
NICE TA439: Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
NICE TA473: Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck